The latest immunotherapy news and developments
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with…
Among patients with advanced melanoma, those who received both nivolumab (Opdivo) and ipilimumab (Yervoy) had…
Although most patients with relapsed B-cell acute lymphoblastic leukaemia (B-ALL) experienced complete response after treatment…
A recent small trial in 15 cancer patients with advanced soft-tissue sarcomas aimed to find…
The immunotherapeutic avelumab (Bavencio) was well tolerated by patients with advanced Merkel cell carcinoma, and…
Among patients with metastatic triple-negative breast cancer (TNBC) who were treated with the anti-PD-L1 cancer…
A University of Queensland researcher has found patients with non-hodgkins lymphoma are most likely to…
Fabian V. Filipp, University of California, Merced Molecular insight into our own DNA is now…
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways…
Building on their previous research focusing on vaccination within a tumour (intratumoural) for the most…